Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179719 | 1.00 | MKNK1 (0.55) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL165154 | 1.00 | MKNK1 (0.55) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL3717223 | 0.94 | MEN1 (0.51) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL8541954 | 0.92 | MEN1 (0.50) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL7672102 | 0.92 | MEN1 (0.50) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL11510901 | 0.89 | MKNK1 (0.48) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL25625502 | 0.85 | MAPT (0.48) | MKNK1CHRNB2CHRNA4CYP2D6MEN1 | |
| SCHEMBL24775559 | 0.81 | CHRNB2 (0.52) | MKNK1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL21507863 | 0.80 | MEN1 (0.42) | MKNK1CHRNB2CHRNA4CYP2D6MEN1 | |
| SCHEMBL6557404 | 0.79 | CHRNB2 (0.50) | MKNK1CHRM2CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | Micro Labs Ltd. (IN) | 2022-05-31 | — | — | US | disclosed |
| US-20210094918-A1 | PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL,ITS SALTS AND POLYMORPHS | Micro Labs Ltd. (IN) | 2021-04-01 | — | — | US | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| WO-2021001713-A1 | PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL, ITS SALTS & POLYMORPHS | MICRO LABS LIMITED (IN) | 2021-01-07 | — | — | WO | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | MKNK1 2542/4885CHRM2 24/4885CHRM5 142/4885 |
| US-20210094918-A1 | PROCESS FOR THE PREPARATION OF (S)-NETARSUDIL,ITS SALTS AND POLYMORPHS | VKORC1L1, CYP3A4, REN | MKNK1 2491/4885CHRM2 1589/4885CHRM5 1719/4885 |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | MKNK1 2542/4885CHRM2 24/4885CHRM5 142/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | MKNK1 3303/4885CHRM2 640/4885CHRM5 499/4885 |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | BRD4, BICRA, NDUFC2 | MKNK1 2542/4885CHRM2 24/4885CHRM5 142/4885 |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | VKORC1L1, CYP3A4, REN | MKNK1 2491/4885CHRM2 1589/4885CHRM5 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.